Sex hormone replacement therapy reverses altered venous contractility in rats after pharmacological ovariectomy. 2002

Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
Second Department of Obstetrics and Gynecology, Semmelweis University, Faculty of Medicine, Budapest, Hungary.

OBJECTIVE Female sex hormones have several important effects on the venous system. We earlier found that hormone replacement has a significant effect on venous distensibility, but effects of menopause and hormone replacement on venous contractility have never been studied. Therefore, and because the changes we found earlier in distensibility were most likely caused by alterations of contractility, we examined the changes in contractility of saphenous vein caused by depletion and replacement of sex hormones in female rats. METHODS Twenty Sprague-Dawley rats were pharmacologically ovariectomized by triptorelin. Ten of these rats received combined sex hormone replacement (HRT) with estradiol propionate and medroxyprogesterone acetate. The rest were given vehicle. Ten animals without ovariectomy served as controls. After 3 months of treatment, segments of the saphenous vein were dissected. Pressure-diameter curves were recorded in relaxed, contracted, and control states. RESULTS Venous diameter, adjusted for body weight, was significantly decreased after pharmacological ovariectomy. HRT increased the diameter. The presence of sex hormones augmented norepinephrine contraction measured at physiological pressures (control: 19.2 +/- 2.3%; pharmacological ovariectomy: 15.2 +/- 1.4%, p < 0.05 and 17.8 +/- 2.2% following HRT). Myogenic (spontaneous) tone of the saphenous vein did not change after ovariectomy, but it was lowered by hormone replacement (control: 8 +/- 1.1%; ovariectomy: 6.9 +/- 2.5%; ovariectomy + HRT: 2.7 +/- 1.1%, p < 0.05). CONCLUSIONS Sex hormone depletion induces significant alterations in contractility of the saphenous vein, which could perturb venous capacitance function and distensibility. This effect has a potential role in the development of hypertension and venous varicosity, and these changes could possibly be prevented by HRT.

UI MeSH Term Description Entries
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010052 Ovariectomy The surgical removal of one or both ovaries. Castration, Female,Oophorectomy,Bilateral Ovariectomy,Bilateral Ovariectomies,Castrations, Female,Female Castration,Female Castrations,Oophorectomies,Ovariectomies,Ovariectomies, Bilateral,Ovariectomy, Bilateral
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012501 Saphenous Vein The vein which drains the foot and leg. Saphenous Veins,Vein, Saphenous,Veins, Saphenous
D014655 Vascular Resistance The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT. Peripheral Resistance,Total Peripheral Resistance,Pulmonary Vascular Resistance,Systemic Vascular Resistance,Peripheral Resistance, Total,Resistance, Peripheral,Resistance, Pulmonary Vascular,Resistance, Systemic Vascular,Resistance, Total Peripheral,Resistance, Vascular,Vascular Resistance, Pulmonary,Vascular Resistance, Systemic
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
January 2001, Menopause (New York, N.Y.),
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
January 2008, Advances in gerontology = Uspekhi gerontologii,
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
August 1993, Fertility and sterility,
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
October 2018, VASA. Zeitschrift fur Gefasskrankheiten,
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
November 2002, Life sciences,
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
February 2004, Cardiovascular research,
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
July 2014, The Journal of steroid biochemistry and molecular biology,
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
September 1999, Climacteric : the journal of the International Menopause Society,
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
December 2001, European journal of internal medicine,
Szabolcs Várbíró, and Zoltán Vajó, and György L Nádasy, and Emil Monos, and Nándor Acs, and Miklós Lóránt, and James V Felicetta, and Béla Székacs
September 2004, Gynecologie, obstetrique & fertilite,
Copied contents to your clipboard!